Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:NTRP

Neurotrope (NTRP) Stock Price, News & Analysis

Neurotrope logo

About Neurotrope Stock (NASDAQ:NTRP)

Key Stats

Today's Range
$1.76
$1.87
50-Day Range
$0.92
$1.05
52-Week Range
$0.68
$3.85
Volume
8,692 shs
Average Volume
34,835 shs
Market Capitalization
$2.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.

Neurotrope Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
6th Percentile Overall Score

NTRP MarketRank™: 

Neurotrope scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Neurotrope.

  • Earnings Growth

    Earnings for Neurotrope are expected to grow in the coming year, from ($0.91) to ($0.10) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Neurotrope is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Neurotrope is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Neurotrope has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Neurotrope's valuation and earnings.
  • Percentage of Shares Shorted

    1.91% of the float of Neurotrope has been sold short.
  • Short Interest Ratio / Days to Cover

    Neurotrope has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Neurotrope has recently increased by 6.67%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Neurotrope does not currently pay a dividend.

  • Dividend Growth

    Neurotrope does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.91% of the float of Neurotrope has been sold short.
  • Short Interest Ratio / Days to Cover

    Neurotrope has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Neurotrope has recently increased by 6.67%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Neurotrope this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Neurotrope insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.70% of the stock of Neurotrope is held by insiders.

  • Percentage Held by Institutions

    Only 3.81% of the stock of Neurotrope is held by institutions.

  • Read more about Neurotrope's insider trading history.
Receive NTRP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurotrope and its competitors with MarketBeat's FREE daily newsletter.

NTRP Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
NextTrip Inc NTRP
See More Headlines

NTRP Stock Analysis - Frequently Asked Questions

Neurotrope, Inc. (NASDAQ:NTRP) issued its quarterly earnings results on Tuesday, October, 30th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.05.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neurotrope investors own include Sarepta Therapeutics (SRPT), Neos Therapeutics (NEOS), Fibrocell Science (FCSC), Bristol-Myers Squibb (BMY), Intel (INTC), Meta Platforms (META) and Pfizer (PFE).

Company Calendar

Last Earnings
10/30/2018
Today
11/12/2024
Next Earnings (Estimated)
1/21/2025
Fiscal Year End
2/28/2025

Industry, Sector and Symbol

Industry
Transportation services
Sub-Industry
N/A
Current Symbol
NASDAQ:NTRP
Employees
5
Year Founded
N/A

Profitability

Pretax Margin
-905.46%

Debt

Sales & Book Value

Annual Sales
$630,000.00
Book Value
$3.34 per share

Miscellaneous

Free Float
1,283,000
Market Cap
$2.41 million
Optionable
No Data
Beta
1.67
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:NTRP) was last updated on 11/13/2024 by MarketBeat.com Staff
From Our Partners